Matthias Preusser mainly focuses on Pathology, Cancer research, Immunohistochemistry, Cancer and Melanoma. His research is interdisciplinary, bridging the disciplines of Biomarker and Pathology. His Cancer research study incorporates themes from Mutant protein, Mutant and Epidermal growth factor receptor.
His research integrates issues of Mutation, Antibody and CD8, Tumor-infiltrating lymphocytes in his study of Immunohistochemistry. His Cancer research is multidisciplinary, incorporating perspectives in Progressive disease, Oncology and Cell adhesion molecule. His Melanoma research integrates issues from Lung cancer, Angiogenesis and Radiation therapy.
His main research concerns Internal medicine, Oncology, Pathology, Cancer research and Cancer. His work in the fields of Internal medicine, such as Breast cancer, Lung cancer and Radiation therapy, intersects with other areas such as In patient. Matthias Preusser combines subjects such as Clinical trial, Surgery, Chemotherapy, Metastatic breast cancer and Cohort with his study of Oncology.
His Pathology research is multidisciplinary, relying on both Primary tumor, Melanoma and Glioma. His Cancer research study combines topics in areas such as Mutation, V600E and Antibody. He interconnects CD8 and Tumor-infiltrating lymphocytes in the investigation of issues within Immunohistochemistry.
Matthias Preusser spends much of his time researching Internal medicine, Oncology, Cancer, Cancer research and Cohort. His study in the field of Hazard ratio, Confidence interval and Brain metastasis also crosses realms of In patient. Matthias Preusser combines subjects such as Immunohistochemistry, Pathology and CD8 with his study of Brain metastasis.
His research in Oncology tackles topics such as Breast cancer which are related to areas like Radiation therapy. The study incorporates disciplines such as Venous thromboembolism, Melanoma and Cohort study in addition to Cancer. Matthias Preusser has included themes like Immune checkpoint, Immunotherapy and Downregulation and upregulation in his Cancer research study.
His primary scientific interests are in Internal medicine, Oncology, Clinical trial, Gastroenterology and Radiation therapy. His work on ROS1 as part of his general Oncology study is frequently connected to Current management, thereby bridging the divide between different branches of science. His biological study spans a wide range of topics, including Molecular pathogenesis, Intensive care medicine, Brain tumor, Pharmacotherapy and Glioblastoma.
Matthias Preusser usually deals with Hazard ratio and limits it to topics linked to Incidence and Melanoma, Immune checkpoint inhibitors, Complication, Intracranial pressure and Lung cancer. His work carried out in the field of Surgery brings together such families of science as Colorectal cancer and Breast cancer. His Primary tumor study incorporates themes from Adult patients and Pathology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
DNA methylation-based classification of central nervous system tumours
David Capper;David Capper;David Capper;David T. W. Jones;Martin Sill;Volker Hovestadt.
European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas
Michael Weller;Martin van den Bent;Jörg C Tonn;Roger Stupp.
Lancet Oncology (2017)
Assessment of BRAF V600E mutation status by immunohistochemistry with a mutation-specific monoclonal antibody
David Capper;David Capper;Matthias Preusser;Matthias Preusser;Antje Habel;Felix Sahm;Felix Sahm.
Acta Neuropathologica (2011)
Current concepts and management of glioblastoma.
Matthias Preusser;Sandrine de Ribaupierre;Adelheid Wöhrer;Sara C. Erridge.
Annals of Neurology (2011)
Brain tumour cells interconnect to a functional and resistant network
Matthias Osswald;Matthias Osswald;Erik Jung;Erik Jung;Felix Sahm;Felix Sahm;Gergely Solecki;Gergely Solecki.
Delta-like 4 Notch Ligand Regulates Tumor Angiogenesis, Improves Tumor Vascular Function, and Promotes Tumor Growth In vivo
Ji-Liang Li;Richard C.A. Sainson;Wen Shi;Russell Leek.
Cancer Research (2007)
Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma
Anna Sophie Berghoff;Barbara Kiesel;Georg Widhalm;Orsolya Rajky.
EANO guidelines for the diagnosis and treatment of meningiomas
Roland Goldbrunner;Giuseppe Minniti;Matthias Preusser;Michael D. Jenkinson.
Lancet Oncology (2016)
DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis
Felix Sahm;Felix Sahm;Daniel Schrimpf;Damian Stichel;David T.W. Jones.
Lancet Oncology (2017)
Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group Part 2 TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non–Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors
Shona Hendry;Roberto Salgado;Thomas Gevaert;Prudence A. Russell;Prudence A. Russell.
Advances in Anatomic Pathology (2017)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: